Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2017 - 2020)

Summit Therapeutics (SMMT) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $2.1 million the latest figure, recorded in Q3 2020.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $2.1 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $2.1 million (changed N/A YoY) and the FY2019 annual result came in at $2.1 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability slipped to $2.1 million in Q3 2020 per SMMT's latest filing, from $2.2 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for SMMT reached as high as $3.3 million in Q2 2018 and fell as low as $701273.5 in Q1 2017.
• A 4-year average of $2.2 million and a median of $2.1 million in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2018 — Non-Current Deferred Tax Liability surged 357.18% — and 2019, when it tumbled 33.03%.
• Year by year, Non-Current Deferred Tax Liability stood at $701273.5 in 2017, then jumped by 215.9% to $2.2 million in 2018, then dropped by 9.46% to $2.0 million in 2019, then increased by 5.1% to $2.1 million in 2020.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.1 million, $2.2 million, and $2.0 million for Q3 2020, Q1 2020, and Q4 2019 respectively.